Product Description
The protein encoded by this gene is a polypeptide hormone whose actions appear to be restricted to the nervous system where it promotes neurotransmitter synthesis and neurite outgrowth in certain neuronal populations. The protein is a potent survival factor for neurons and oligodendrocytes and may be relevant in reducing tissue destruction during inflammatory attacks. (Sourced from: https://www.ncbi.nlm.nih.gov/gene/1270)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Retinitis Pigmentosa|Usher Syndromes|Telangiectasis|Color Vision Defects
Phase 1: Optic Nerve Diseases|Optic Neuropathy, Ischemic|Ischemic Stroke|Optic Neuritis|Glaucoma, Open-Angle|Retinitis Pigmentosa
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NTMT-01/02E | P2 |
Completed |
Telangiectasis |
2021-05-11 |
24% |
| AOSLO-CNTF-FFB-01 | P2 |
Completed |
Retinitis Pigmentosa|Usher Syndromes |
2019-07-01 |
|
| NTMT-02 | P2 |
Completed |
Telangiectasis |
2017-04-14 |
22% |
| NCT01408472 | P1 |
Completed |
Glaucoma, Open-Angle |
2013-12-01 |